Laidlaw reiterated their hold rating on shares of iCAD (NASDAQ:ICAD - Free Report) in a research note issued to investors on Thursday, Marketbeat.com reports.
Other equities research analysts have also recently issued research reports about the stock. BTIG Research cut shares of iCAD from a "buy" rating to a "neutral" rating in a research note on Wednesday. StockNews.com upgraded shares of iCAD from a "sell" rating to a "hold" rating in a research report on Wednesday, March 26th.
Check Out Our Latest Stock Report on iCAD
iCAD Price Performance
NASDAQ ICAD traded up $0.15 during trading on Thursday, hitting $3.22. The company's stock had a trading volume of 2,015,939 shares, compared to its average volume of 356,012. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The company has a market cap of $88.12 million, a PE ratio of -24.77 and a beta of 1.78. The business's 50 day simple moving average is $2.35 and its 200-day simple moving average is $2.14.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. The firm had revenue of $5.41 million during the quarter, compared to analysts' expectations of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
Institutional Trading of iCAD
A number of hedge funds and other institutional investors have recently modified their holdings of ICAD. Summit Trail Advisors LLC acquired a new stake in iCAD during the fourth quarter worth about $214,000. Granahan Investment Management LLC acquired a new position in shares of iCAD in the 4th quarter valued at $96,000. Integrated Wealth Concepts LLC purchased a new position in shares of iCAD during the 4th quarter worth $92,000. First Eagle Investment Management LLC increased its position in shares of iCAD by 6.1% during the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock worth $1,311,000 after purchasing an additional 41,000 shares during the last quarter. Finally, PKS Advisory Services LLC acquired a new position in iCAD in the fourth quarter valued at about $53,000. 24.61% of the stock is owned by institutional investors and hedge funds.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
